藥學(xué)專業(yè)文章寫作

1、藥品中英文說明書English writing1How to write?Translate Chinese into English2. Consult interrelated English paper (article) 2ReviewShot communicationLetter to editorReserch(regular) articleTypes of articles3Structure of articleTitle(author, affiliation,address)AbstractIntroductionMaterials and MethodsResults

2、DiscussionReferencesAcknowledgments4摘要的書寫How to write abstract in English?5Structure of abstract目的 (Objective)方法 (Methods)結(jié)果 (Results)結(jié)論(Conclusions) 關(guān)鍵詞（key words)6摘要的書寫摘要的時態(tài)(Tense,The passive voice)詞的活用（ Active choice of words)關(guān)鍵詞的選擇（Active choice of the key words)7(Example 1)電泳光散射法測定異丙酚微乳劑的動電電位 T

3、he measurements of the zeta potential of Propofol micro-emulsion by the electrophoretic light scattering (ELS) method8 Abstract: Objective The zeta potentials of the Propofol micro-emulsion were measured by using electrophoretic light scattering (ELS) and a convenient, rapid, and effective method of

4、 physical stability study was provided for an ultra-fine dispersion preparation.摘要：目的 采用電泳光散射法測定異丙酚微乳劑的動電電位, 為微多相藥物制劑物理穩(wěn)定性的考察提供簡便、快速、有效的方法。9 Methods Three preparations named as emulsion、emulsion and emulsion respectively and had the same procedures but different recipes had been made. Their ELS spec

5、tra were obtained by the Nicomp 380/ZLS system.方法 制備三種處方不同、工藝相同的異丙酚微乳劑、及，以NICOMP380/ZLS系統(tǒng)分別測定其電泳光散射光譜。10結(jié)果 與無外加電場情況相比，有外加電場時，乳劑、和的光譜譜線向左頻移分別為（29.820.12）、（12.540.44）及（20.181.12）Hz，相應(yīng)電動電位為（45.400.04）, （19.091.12）與 (30.720.46) mV Results Compared with the unapplied electric field, the main peak with ap

6、plied electric field showed the left shifting, the values were (29.820.12), (12.540.44), and (20.181.12)Hz, separately. The corresponding zeta potentials were (45.400.04), (19.091.12), and (30.720.46) mV.11結(jié)論 三種微乳劑電泳光散射光譜有顯著差別，動電電位的大小順序為乳劑乳劑乳劑。Conclusions Three preparations had differences clearly i

7、n ELS spectra. The order for the micro-emulsion zeta potentials was emulsion, emulsion , and emulsion.12關(guān)鍵詞：電泳光散射；微乳劑；動電電位Key words: electrophoretic light scattering; micro-emulsion; zeta potential13摘要的時態(tài)(Tense)1.(The past tense)過去時2. (The past perfect tense)過去完成時3. (The present tense, sometimes)現(xiàn)在時

8、14一般不超過8個(Less than 8 words)小寫 (Small write)分號分開(; separately)key words15(Example 2)口服胰島素微粒劑的研究 Studies on the insulin microparticles preparation for oral administration16 主要研究口服胰島素微粒劑的處方、制備、性質(zhì)、藥效學(xué)、大鼠胃腸道有效吸收部位、絕對生物利用度及小鼠體內(nèi)分布。 摘要 (ABSTRACT) Prescriptions, preparations, properties, pharmacodynamics, a

9、ctive absorption sites in diabetic rats gastrointestinal tract, absolute bioavailability and distribution of the oral insulin micro-particles (INS-MP) in mice body are mainly studied in this article.17Taking bioactivity-blood glucose level in mice as index and using tertiary phase-diagram, orthogona

10、l design optimization and verification of formation conditions of insulin-gelatin complex, the insulin combination efficiency in this complex was determined to be more than 86% according to the method of insulin potency. 以生物活性小鼠血糖水平為指標(biāo)，利用三角相圖、正交設(shè)計優(yōu)化并確定了胰島素明膠復(fù)合物（胰島素明膠）形成條件；采用胰島素生物效價法測得該復(fù)合物胰島素結(jié)合率在86%以

11、上；18 給小鼠灌服35u/kg，兩小時血糖降低35.70.29（%）；對復(fù)合物的荷電狀況、差熱分析曲線、紅外吸收光譜以及X-射線衍射圖譜等分析，驗證了復(fù)合物的理化性質(zhì)與其單組分、物理混合狀態(tài)不同，對該部分研究未見文獻(xiàn)報道。Blood glucose level was reduced by 35.70.29(%) after 2 hours of perfusing mice with 35u/kg of this preparation. The physical-chemical properties of the complex were different from those of

12、 its single component and physical mixture, which was vertified by analysis of electro-charging state, differential thermo-analysic curve, infrared absorption spectrum and X-rays diffraction pattern of this complex and the study above hadnt been reported.19 Key words: insulin; gelatin; complex; micr

13、oparticles; hypoglycemia; absolute bioavailability關(guān)鍵詞：胰島素；明膠；復(fù)合物；微粒劑； 降血糖；絕對生物利用度20Please put the following Chinese into English國家藥監(jiān)局納米制劑 16目-篩 腸衣片有效期 國產(chǎn)藥 一次性注射器 藥房 無菌操作SFDANano-preparation16-mesh screenenteric coating tabletsshelf lifeindigenous drugs, domestic drugsdisposable syringepharmacyasepti

14、c technique21緩釋制劑I期臨床試驗多層片delayed released preparation, prolonged released preparation, sustained released preparationI clinical trialsmultiple layered tabletsPlease put the following Chinese into English22exercise A Phase II Randomized Study of Two Taxanes and Cisplatin for Metastatic Breast Cancer

15、 after Anthracycline: A Final Analysis. Jpn J clin oncol,2006, DEC,15 (ahead of print) Lin YC,Chang HK,Chen JS, Wang HM23 OBJECTIVE: The purpose of the study is to compare two taxanes/cisplatin combinations for metastatic breast cancer in terms of time to disease progression, response rates and toxi

16、city. METHODS: Between April 2000 and December 2002, 101 patients with advanced breast carcinoma, previously treated with an anthracycline but not with a taxane, were enrolled. Fifty patients were treated with docetaxel 60 mg/m(2) and cisplatin 50 mg/m(2), and 51 patients were treated with paclitaxe

17、l 175 mg/m(2) and cisplatin 50 mg/m(2). Each cycle repeated every 3 weeks. 24 RESULTS: The overall response rate was 62.5 and 42.6% in the docetaxel and palcitaxel groups respectively (P=0.06). Median time to disease progression was 9.8 and 6.5 months in docetaxel and paclitaxel groups respectively (P=0.15). The median overall survival time was 22.7 months in the docetaxel arm and 22.4 months in the paclitaxel arm. Grade 3/4 arthralgia/myalgia, sensory neuropathy and anemia occurred more frequently in the paclitaxel arm, while more mucositis, fatigue and neutropenia occur